JD on Stockhouse posted: "Have you ever noticed that neither Denali nor any other Bioasis competitor is targeting brain tumours with the transport with monoclonal antibody (MAB) fusion proteins across the BBB like Bioasis is. Why not?"

Great question. Especially relevant to Angiochem who, like BiOasis, has a short peptide that binds LRP-1 receptor. Recall Angiochem and their lead angiopep-2 peptide has completed Phase 2 trials with their paclitaxel conjugate. They have entered into a license agreement for this program with China and have stated plans for a Phase 3. Furthermore, Angiochem has presented pre-clinical data back in 2014 on their ANG4043 chemical conjugate of Angiopep-2 (An2) with an anti-HER2 mAb (Trastuzumab?).

I would appreciate Mark Day, JD or others providing a reminder of the advantages of xB3 over Angiopep-2, especially in light of them both being LRP-1 receptor ligands. Why has Angiochem stalled? What differentiates xB3 from Angiopep-2? 

BearDownAZ